Other · developed by Vifor Pharma
Patiromer is a non-absorbed cation exchange polymer with a calcium-sorbitol counterion that binds potassium in the gastrointestinal lumen, increasing fecal potassium excretion and lowering serum potassium. It is studied in hyperkalemia and chronic renal insufficiency.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jan 31, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05136664 | Phase 3 | Hyperkalemia | Completed | FMS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
HyperkalemiaRenal Insufficiency, Chronic
Updated Nov 8, 2026.